miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

Cai, Xiaopan; Peng, Dongyu; Wei, Haifeng; Yang, Xianghong; Huang, Quan; Zx, Lin; Xu, Wei; Qian, Ming; Yang, Cheng; Liu, Tielong; Yan, Wangjun; Zhao, Jian

doi:10.3892/ol.2017.5692

Cited by 26 publications

(22 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, new prognostic markers and treatment options are urgent for the improvement of medical treatment for patients with breast cancer. Previous investigations have determined that miR‐215 serves as an anti‐oncogene in several kinds of cancers, but the mechanisms by which miR‐215‐5p is involved in breast carcinoma progression have not been effectively studied . This current study reveals that miR‐215‐5p is down‐regulated in breast cancer and is negatively correlated with the progression and metastasis of breast carcinoma.…”

Section: Discussionmentioning

confidence: 66%

miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells by targeting Sox9

Gao

Zhu

2019

FEBS Open Bio

View full text Add to dashboard Cite

Several studies have shown that miR‐215‐5p acts as a tumor suppressor in certain cancers, but its role in the progression and metastasis of breast carcinoma remains incompletely understood. Herein, we prove that miR‐215‐5p is substantially down‐expressed in breast carcinoma as compared with nontumor tissue. Up‐regulation of miR‐215‐5p inhibits the aggressive abilities of breast carcinoma cells in vitro. We performed luciferase reporter tests to show that SRY‐Box 9 (Sox9) is the target of miR‐215‐5p; as predicted, Sox9 depletion replicates the suppressive effects of miR‐215‐5p on breast carcinoma cells, and overexpression of Sox9 rescues the effects of miR‐215‐5p on breast cancer cell progression. In addition, a xenograft model assay was used to reveal that miR‐215‐5p inhibits breast cancer cell growth and metastatic potential in vivo. Overall, these results imply that miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells through targeting Sox9.

show abstract

Section: Discussionmentioning

confidence: 66%

miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells by targeting Sox9

Gao

Zhu

2019

FEBS Open Bio

View full text Add to dashboard Cite

show abstract

“…36 miR-215 exhibited not only tumor suppression but also tumor promotion function in some cancer types such as non-small cell lung cancer, gastric cancer and glioma, which indicated its dual function in cancer development. [37][38][39][40][41] For miR-146-5p, a member of miR-16 family, it was supposed to be a tumor suppressor for various cancers, [42][43][44] but little was known about its role in BC. On the contrary, miR-210 could be a tumor promoter, which was reported to be associated with poor prognosis for BC patients via different biological pathways such as hypoxia induction, invasive transformation and tumor proliferation promotion.…”

Section: Discussionmentioning

confidence: 99%

A five‐miRNA panel in plasma was identified for breast cancer diagnosis

Zou

Xia

et al. 2019

Cancer Medicine

View full text Add to dashboard Cite

Breast cancer (BC) is one of the most common cancers in females. Since early detection can bring prognosis benefit, discovery of novel noninvasive biomarkers for BC diagnosis is in urgent need. In this four‐phase study, we profiled miRNA expression in plasma samples from a total of 257 BC patients and 257 normal controls (NCs). Exiqon miRNA qPCR panel was used to select candidate miRNAs in the screening phase which were further analyzed using qRT‐PCR in the following training, testing and external validation phases. Finally, we identified five plasma miRNAs (let‐7b‐5p, miR‐122‐5p, miR‐146b‐5p, miR‐210‐3p and miR‐215‐5p) whose expression levels were significantly different between BC patients and NCs. A 5‐miRNA panel in plasma with high sensitivity and specificity was then constructed to detect BC. The areas under the receiver‐operating characteristic curves (AUCs) of the panel were 0.683, 0.966, 0.978 for the training, testing and external validation sets, respectively. Expression of the identified miRNAs was further analyzed among 32 pairs of BC tissue and the adjacent normal tissue samples as well as plasma‐derived exosome samples from 32 BC patients vs 32 NCs. Let‐7b‐5p was contrarily down‐regulated in BC tissue. In exosomes samples, only miR‐122‐5p was significantly up‐regulated as in plasma for BC patients. In conclusion, we identified a 5‐miRNA plasma panel (let‐7b‐5p, miR‐122‐5p, miR‐146b‐5p, miR‐210‐3p and miR‐215‐5p) that could serve as a promising biomarker for BC detection.

show abstract

“…The miRNA-215-5p Prominently Suppressed HG-Induced MPC5 Cell Migration. It has been demonstrated that miRNA-215 was a negative regulator for cell migration and invasion in many diseases [23][24][25]. When the expression of miRNA-215-5p using mimics in MPC5 cells was forced, its decline was recovered in the presence of HG (Figure 3(a)).…”

Section: The Mir-215-5pmentioning

confidence: 98%

Exosomal miRNA-215-5p Derived from Adipose-Derived Stem Cells Attenuates Epithelial–Mesenchymal Transition of Podocytes by Inhibiting ZEB2

Jin

Wang

Zhao

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Podocyte migration is actively involved in the process of podocyte loss and proteinuria production, which is closely associated with the development of diabetic nephropathy (DN). Exosomes from adipose-derived stem cells (ADSCs-Exos) effectively inhibit podocyte apoptosis in the treatment of DN. However, how ADSCs-Exos affect the migration of podocytes is obscure. This study is aimed at exploring the regulatory role of ADSCs-Exos on cell migration and the underlying mechanism. Methods. ADSCs-Exo was authenticated by transmission electron microscopy (TEM), western blotting, and flow cytometry. Cell viability and migration ability of podocytes were measured by CCK8 and Transwell assays, respectively. Relative expressions of miRNAs and mRNAs were determined by qRT-PCR. The transmitting between PKH26-labeled exosome and podocytes was evaluated by IF assay. Dual luciferase reporter assay was employed to detect the relationship between miR-215-5p and ZEB2. Results. The exposure to serum from DN patient (hDN-serum) significantly inhibited cell viability of podocytes, but ADSCs-Exo addition notably blunts cytotoxicity induced by the transient stimulus of hDN-serum. Besides, ADSCs-Exo administration powerfully impeded high glucose-(HG-) induced migration and injury of podocyte. With the podocyte dysfunction, several miRNAs presented a significant decline under the treatment of HG including miR-251-5p, miR-879-5p, miR-3066-5p, and miR-7a-5p, all of which were rescued by the addition of ADSCs-Exo. However, only miR-251-5p was a key determinant in the process of ADSCs-Exo-mediated protective role on podocyte damage. The miR-251-5p inhibitor counteracted the improvement from the ADSCs-Exo preparation on HG-induced proliferation inhibition and migration promotion. Additionally, miR-215-5p mimics alone remarkably reversed HG-induced EMT process of podocyte. Mechanistically, we confirmed that ADSCs-Exos mediated the shuttling of miR-215-5p to podocyte, thereby protecting against HG-induced metastasis, possibly through inhibiting the transcription of ZEB2. Conclusion. ADSCs-Exo has the protective effect on HG-evoked EMT progression of podocytes thru a mechanism involving ZEB2. Potentially, the ADSCs-Exo preparation is a useful therapeutic strategy for improving podocyte dysfunction and DN symptoms clinically.

show abstract

miR-215 suppresses proliferation and migration of non-small cell lung cancer cells

Cited by 26 publications

References 22 publications

miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells by targeting Sox9

miRNA‐215‐5p suppresses the aggressiveness of breast cancer cells by targeting Sox9

A five‐miRNA panel in plasma was identified for breast cancer diagnosis

Exosomal miRNA-215-5p Derived from Adipose-Derived Stem Cells Attenuates Epithelial–Mesenchymal Transition of Podocytes by Inhibiting ZEB2

Contact Info

Product

Resources

About